Glucagon-like peptide 2 receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Glucagon-like peptide 2 receptor shows approved-linked disease relevance led by short bowel syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O95838. Start with short bowel syndrome, then reuse UniProt O95838 as the stable protein anchor across project notes and exports.
Start with short bowel syndrome, then reuse UniProt O95838 as the stable protein anchor across project notes and exports.
Glucagon-like peptide 2 receptor shows approved-linked disease relevance led by short bowel syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with short bowel syndrome because it currently carries approved-linked support. Linked drugs include FE 203799, TEDUGLUTIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGlucagon-like peptide 2 receptor
Review this target as Glucagon-like peptide 2 receptor, mapped to UniProt O95838. Sequence length is 553 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glucagon-like peptide 2 receptor as ChEMBL target CHEMBL5844, mapped to UniProt O95838. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Glucagon-like peptide 2 receptor is the right protein anchor across sources, using UniProt O95838 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why short bowel syndrome is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Glucagon-like peptide 2 receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O95838 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Glucagon-like peptide 2 receptor |
| UniProt Accession | O95838 |
| Component Type | Protein |
| Sequence Length | 553 aa |
Glucagon-like peptide 2 receptor
Review this target as Glucagon-like peptide 2 receptor, mapped to UniProt O95838. Sequence length is 553 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Glucagon-like peptide 2 receptor shows approved-linked disease relevance led by short bowel syndrome. 5 more disease programs remain visible in the same review block.
Start review with short bowel syndrome because it currently carries approved-linked support. Linked drugs include FE 203799, TEDUGLUTIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2104987 | 11.0 | EC50 | 0.01 | Approved |
| CHEMBL4290380 | 10.7 | EC50 | 0.02 | Preclinical |
| CHEMBL3822928 | 10.52 | EC50 | 0.03 | Preclinical |
| CHEMBL3823133 | 10.52 | EC50 | 0.03 | Preclinical |
| CHEMBL3823541 | 10.52 | EC50 | 0.03 | Preclinical |
| CHEMBL3823976 | 10.52 | EC50 | 0.03 | Preclinical |
| CHEMBL3822792 | 10.4 | EC50 | 0.04 | Preclinical |
| CHEMBL3823835 | 10.4 | EC50 | 0.04 | Preclinical |
| CHEMBL3823327 | 10.3 | EC50 | 0.05 | Preclinical |
| CHEMBL3823847 | 10.3 | EC50 | 0.05 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 30 | 94 | 9.5 |
| single protein format | 4 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 12 | 16 | 9.9 |
| assay format | 2 | 0 | — |